Loading
A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer is a phase 2 interventional study registered as NCT07314723 by Mabwell (Shanghai) Bioscience Co., Ltd., with 90 participants planned, started 2025-08-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: 9MW2821 and Toripalimab Injection.
Shares Mabwell (Shanghai) Bioscience, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Bladder & urothelial cancer and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.